Limited-duration Teclistamab

Clinical trial NCT05932680 · RECRUITING

Trial details

NCT number: NCT05932680
Sponsor: Abramson Cancer Center at Penn Medicine
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Myeloma Multiple

Start date: 2023-07-05
Primary completion: 2026-06-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.